Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Detrol La
2. Detrusitol
3. Pha 686464b
4. Pha-686464b
5. Pha686464b
6. Tartrate, Tolterodine
7. Tolterodine
8. Tolterodine Tartrate
9. Unidet
10. Urotrol
1. Tolterodine Tartrate
2. 124937-52-6
3. Detrol La
4. Detrusitol
5. Tolterodine L-tartrate
6. Pnu-200583e
7. (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-methylphenol (2r,3r)-2,3-dihydroxysuccinate
8. Tolterodine Tartrate [usan]
9. Kabi-2234
10. Urotrol
11. 5t619tqr3r
12. Pnu 200583e
13. Tolterodine Tartrate (detrol La)
14. 124937-52-6 (tartrate)
15. Tolterodine (tartrate)
16. (r)-2-(3-diisopropylamino-1-phenyl-propyl)-p-cresol L-tartrate
17. (r)-2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methylphenol (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt)
18. (+)-(r)-2-(i-(2-(diisopropylamino)ethyl)benzyl)-p-cresol L-tartrate (1:1) (salt)
19. Unii-5t619tqr3r
20. (2r,3r)-2,3-dihydroxybutanedioic Acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
21. Detrusitol Sr
22. Mfcd07771985
23. (r)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol L-tartrate
24. Detrusitol (tn)
25. Detrol (tn)
26. Tolterodine, Tartrate
27. (tolterodine Tartrate)
28. Detrol La;kabi-2234;pnu-200583e
29. Tolterodine Tartrate,(s)
30. (r)-tolterodine L-tartrate
31. Tolterodine Tartrate- Bio-x
32. Mls003915640
33. Schembl467372
34. Chembl1200871
35. Tolterodine Tartrate (jan/usp)
36. Dtxsid80924972
37. Tolterodine Tartrate [mi]
38. Hms3715n08
39. Hms3884j08
40. Tolterodine Tartrate [jan]
41. Tolterodine Tartrate [vandf]
42. S2550
43. Tolterodine Tartrate [mart.]
44. Tolterodine Tartrate [usp-rs]
45. Akos015961803
46. Ac-2617
47. Ccg-221263
48. Cs-0441
49. Ds-1398
50. Tolterodine L-tartrate [who-dd]
51. Tolterodine L-tartrate 124937-51-5
52. (2r,3r)-2,3-dihydroxybutanedioic Acid,2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
53. As-35344
54. Bt164484
55. Hy-90010
56. Phenol, 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-, (2r,3r)-2,3-dihydroxybutanedioate (1:1) (salt)
57. Phenol, 2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-, (r)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt)
58. Smr002544692
59. Tolterodine L-tartrate, >=98% (hplc)
60. Tolterodine Tartrate [orange Book]
61. Bcp0726000292
62. Tolterodine Tartrate [ep Monograph]
63. Tolterodine Tartrate [usp Monograph]
64. Sw197495-2
65. D01148
66. (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-
67. 4-methylphenol (2r,3r)-2,3-dihydroxysuccinate
68. 937t526
69. A890340
70. J-500064
71. Q27114836
72. (+)-(r)-2-(a-[2-(diisopropylamino)ethyl]benzyl)-p-cresol Tartrate
73. (+)-r)-2-{a-(2-(diisopropylamino)ethyl)benzyl}-p-cresol Tartrate
74. (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-methylphenol(2r,3r)-2,3-dihydroxysuccinate
75. (r)-2-(3-diisopropylamino-1-phenyl-propyl)-4-methyl-phenol L-tartrate
76. 2-[(1r)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol (2r,3r)-2,3-dihydroxybutanedioate
| Molecular Weight | 475.6 g/mol |
|---|---|
| Molecular Formula | C26H37NO7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 10 |
| Exact Mass | 475.25700252 g/mol |
| Monoisotopic Mass | 475.25700252 g/mol |
| Topological Polar Surface Area | 139 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 474 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Detrol |
| PubMed Health | Tolterodine (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | DETROL Tablets contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (R)-2-[3-[bis(1-methylethyl)-amino]1-phenylpropyl]-4-methylphenol [R-(R*,R*)]-2,3dihydroxyb... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2mg; 1mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 6 | |
|---|---|
| Drug Name | Detrol la |
| Drug Label | DETROL LA Capsules contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine L-hydrogen tartrat... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 4mg; 2mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 3 of 6 | |
|---|---|
| Drug Name | Tolterodine tartrate |
| PubMed Health | Tolterodine (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | Tolterodine tartrate tablets contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (+)-(R)-2-[I-[2-(Diisopropylamino)ethyl]benzyl]-p-cresol L-tartrate (1:1) (sa... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Tablet; Capsule, extended release |
| Route | oral; Oral |
| Strength | 1mg; 4mg; 2mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Sandoz |
| 4 of 6 | |
|---|---|
| Drug Name | Detrol |
| PubMed Health | Tolterodine (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | DETROL Tablets contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (R)-2-[3-[bis(1-methylethyl)-amino]1-phenylpropyl]-4-methylphenol [R-(R*,R*)]-2,3dihydroxyb... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2mg; 1mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 5 of 6 | |
|---|---|
| Drug Name | Detrol la |
| Drug Label | DETROL LA Capsules contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine L-hydrogen tartrat... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 4mg; 2mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 6 of 6 | |
|---|---|
| Drug Name | Tolterodine tartrate |
| PubMed Health | Tolterodine (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | Tolterodine tartrate tablets contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (+)-(R)-2-[I-[2-(Diisopropylamino)ethyl]benzyl]-p-cresol L-tartrate (1:1) (sa... |
| Active Ingredient | Tolterodine tartrate |
| Dosage Form | Tablet; Capsule, extended release |
| Route | oral; Oral |
| Strength | 1mg; 4mg; 2mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Apotex; Sandoz |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
50
PharmaCompass offers a list of Tolterodine Tartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tolterodine Tartrate manufacturer or Tolterodine Tartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tolterodine Tartrate manufacturer or Tolterodine Tartrate supplier.
PharmaCompass also assists you with knowing the Tolterodine Tartrate API Price utilized in the formulation of products. Tolterodine Tartrate API Price is not always fixed or binding as the Tolterodine Tartrate Price is obtained through a variety of data sources. The Tolterodine Tartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A H029 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of H029, including repackagers and relabelers. The FDA regulates H029 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. H029 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of H029 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A H029 supplier is an individual or a company that provides H029 active pharmaceutical ingredient (API) or H029 finished formulations upon request. The H029 suppliers may include H029 API manufacturers, exporters, distributors and traders.
click here to find a list of H029 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A H029 DMF (Drug Master File) is a document detailing the whole manufacturing process of H029 active pharmaceutical ingredient (API) in detail. Different forms of H029 DMFs exist exist since differing nations have different regulations, such as H029 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A H029 DMF submitted to regulatory agencies in the US is known as a USDMF. H029 USDMF includes data on H029's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The H029 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of H029 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a H029 Drug Master File in Korea (H029 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of H029. The MFDS reviews the H029 KDMF as part of the drug registration process and uses the information provided in the H029 KDMF to evaluate the safety and efficacy of the drug.
After submitting a H029 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their H029 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of H029 suppliers with KDMF on PharmaCompass.
A H029 CEP of the European Pharmacopoeia monograph is often referred to as a H029 Certificate of Suitability (COS). The purpose of a H029 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of H029 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of H029 to their clients by showing that a H029 CEP has been issued for it. The manufacturer submits a H029 CEP (COS) as part of the market authorization procedure, and it takes on the role of a H029 CEP holder for the record. Additionally, the data presented in the H029 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the H029 DMF.
A H029 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. H029 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of H029 suppliers with CEP (COS) on PharmaCompass.
A H029 written confirmation (H029 WC) is an official document issued by a regulatory agency to a H029 manufacturer, verifying that the manufacturing facility of a H029 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting H029 APIs or H029 finished pharmaceutical products to another nation, regulatory agencies frequently require a H029 WC (written confirmation) as part of the regulatory process.
click here to find a list of H029 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing H029 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for H029 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture H029 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain H029 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a H029 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of H029 suppliers with NDC on PharmaCompass.
H029 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of H029 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right H029 GMP manufacturer or H029 GMP API supplier for your needs.
A H029 CoA (Certificate of Analysis) is a formal document that attests to H029's compliance with H029 specifications and serves as a tool for batch-level quality control.
H029 CoA mostly includes findings from lab analyses of a specific batch. For each H029 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
H029 may be tested according to a variety of international standards, such as European Pharmacopoeia (H029 EP), H029 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (H029 USP).